Key result
Novel non-peptide renin inhibitors, particularly aliskiren, show efficacy in animal models and early human studies, representing a potential new class of orally-effective antihypertensive agents.
Population
Animal models and humans with cardiovascular diseases such as hypertension and heart failure
Design
Review
Authors
Loading...
Should not yet change hypertension practice; leaves open efficacy of oral renin inhibitors pending definitive trials.
Novel non-peptide renin inhibitors, particularly aliskiren, show promise as a new class of orally-effective treatments for hypertension and cardiovascular disease.
Maibaum et al. (2003) conducted a review in Cardiovascular disease (hypertension and heart failure). Renin inhibitors (3-alkoxy-4-aryl-piperidines and alkanecarboxamides) was evaluated. Novel non-peptide renin inhibitors, particularly aliskiren, show efficacy in animal models and early human studies, representing a potential new class of orally-effective antihypertensive agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: